Stonebridge Herald today published a detailed report examining the FDA's September 28, 2026 approval of Emcitate (tiratricol), the first therapy ever cleared to treat symptoms of MCT8 deficiency, a rare and devastating genetic disorder also known as Allan-Herndon-Dudley syndrome.

The Stonebridge Herald report outlines how Emcitate addresses peripheral thyrotoxicosis in affected patients by allowing its active ingredient to enter cells without relying on the broken MCT8 transporter protein, along with clinical trial results showing reductions in excess thyroid hormone and improvements in blood pressure and heart rate.

The coverage also details the drug's dosing, side effects, regulatory designations including Orphan Drug and Breakthrough Therapy status, and statements from FDA officials on what the approval means for patients and families who previously had no treatment options.

The full report, including background on MCT8 deficiency and reactions from FDA leadership, is available now from Stonebridge Herald.